the protein ubiquitin is an important post-translational modifier that regulates a wide variety of biological processes. in cells, ubiquitin is apportioned among distinct pools, which include a variety of free and conjugated species. Although maintenance of a dynamic and complex equilibrium among ubiquitin pools is crucial for cell survival, the tools necessary to quantify each cellular ubiquitin pool have been limited. We have developed a quantitative mass spectrometry approach to measure cellular concentrations of ubiquitin species using isotope-labeled protein standards and applied it to characterize ubiquitin pools in cells and tissues. our method is convenient, adaptable and should be a valuable tool to facilitate our understanding of this important signaling molecule.
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The protein ubiquitin is a highly conserved post-translational modifier that regulates a wide variety of biological processes in eukaryotes 1, 2 . Most known ubiquitin signaling is initiated by conjugation of ubiquitin to protein substrates and terminated by hydrolysis of this linkage by deubiquitinating enzymes. In the cell, ubiquitin is dynamically apportioned among distinct pools which include 'free' (unconjugated) ubiquitin, 'activated' ubiquitin, which is conjugated via thioester linkages to enzyme-bound intermediates of the ubiquitin conjugation cascade, and peptidelinked conjugates to substrate proteins (Fig. 1a) . The conjugate pool comprises monoubiquitin conjugates, in which one or more ubiquitin is attached to lysine residues on a substrate through an isopeptide linkage between the terminal carboxyl group of ubiquitin and the ε-amino group of the target lysine, and polyubiquitin conjugates, in which additional ubiquitin molecules are attached to the lysine residues in ubiquitin itself, producing substrate-linked polyubiquitin chains.
Much of the complexity of cellular signaling by ubiquitin has been proposed to depend on its ability to form diverse covalent conjugates with other proteins 1 . For instance, attachment of Lys48-linked polyubiquitin chains to substrates is widely held to be the canonical signal for degradation by the proteasome, whereas Lys63-linked polyubiquitination of cell-surface receptors signals internalization by endocytosis, and monoubiquitination of histones regulates chromatin structure 1, 2 . Additionally, free polyubiquitin chains that are not conjugated to substrates have emerging roles in cellular signaling 3 .
Levels of total cellular ubiquitin are regulated by transcriptional control at four different genetic loci and by post-translational mechanisms 1 . Disruption of total ubiquitin levels or the distribution of ubiquitin among different cellular pools is linked to a wide spectrum of diseases including cancer 4 and neurodegeneration 5 . Given the importance of ubiquitin to most aspects of eukaryotic cell function and the recognition of the importance of maintaining ubiquitin homeostasis, the ability to accurately and precisely quantify ubiquitin pools in a cell or tissue is of paramount importance.
Most prior studies of ubiquitin pools have relied on antibodies to discriminate between free and conjugated ubiquitin species 6, 7 . However, because traditional conjugate-selective antibodies react to a finite and indeterminate extent with free ubiquitin and antibodies to free ubiquitin react to an unknown extent with different types of conjugates, it has not been possible to accurately measure ubiquitin pools in biological specimens. Synthetic peptide absolute quantification (AQUA) mass spectrometry has enabled precise quantification of mono-and polyubiquitination of purified substrates and relative quantification of affinitycaptured polyubiquitin species from cell and tissue lysates [8] [9] [10] . However, synthetic peptides cannot account for loss of protein that occurs through fractionation and processing procedures.
We developed a method that combines differential affinity chromatography and protein standard absolute quantification (PSAQ) mass spectrometry 11 to enable the precise measurement of cellular molar concentrations of ubiquitin pool components. Our strategy, termed ubiquitin-PSAQ, uses stable isotope-labeled free ubiquitin and ubiquitin conjugates as recovery standards, which we 'spiked' into cell or tissue lysates and captured with affinity reagents that are selective for free ubiquitin or ubiquitin chains. Using this approach we determined the steady-state distribution of ubiquitin pools in tissue culture cells before and after induction of proteasome stress and in lysates of mouse and human brain. Our data indicate a surprising degree of heterogeneity in the distribution of ubiquitin among intracellular pools in different cell types and tissues and in the dynamic responses of these pools among different cell types. These findings constitute precise measurements of ubiquitin pool distribution and dynamics in a living system and have broad utility for enhancing our understanding of this important cellular signaling modifier.
results

Assay design
To measure cellular ubiquitin pools by quantitative mass spectrometry, we devised an approach (Ub-PSAQ) that combines the use of differential affinity chromatography (Fig. 1b) and isotopelabeled ubiquitin recovery standards ( Fig. 1c and Supplementary  Fig. 1 ). We prepared [ 13 15 N]ubiquitin-GFP recovery standards. We divided samples into two equal portions then diluted them to reduce the SDS concentration to below 0.05%. One portion we used to determine total ubiquitin concentration after conversion of all ubiquitin conjugates to free ubiquitin with the catalytic domain of the deubiquitinating enzyme usp2cc 12 (Fig. 1c) . We isolated free ubiquitin species from this portion and from the portion not treated with deubiquitinating enzyme by exploiting the ability of the zinc-finger domain from isopeptidase T (BUZ) to bind specifically to the free C-terminal diglycine motif of ubiquitin 13 (Fig. 1b) . To confirm that our lysis conditions prevented deubiquitinating-enzyme activity, we monitored binding of the [ 15 N, 13 C]ubiquitin-GFP standard by the BUZ affinity reagent in all samples and observed none when samples were lysed in the presence of 2% SDS and 5 mg ml −1 N-ethylmaleimide (NEM). We isolated polyubiquitin chains by affinity capture with the human PLIC2 ubiquitin-association domain (hP2 UBA) as previously described 8 (Fig. 1b) . To maximize conversion of conjugated ubiquitin to free ubiquitin, we used a molar excess of usp2cc to ubiquitin and monitored the extent of cleavage both as the loss of all ubiquitin chain linkages bound to hP2 UBA and as the increase of [ 15 N, 13 C]ubiquitin binding to the BUZ domain (Supplementary Data 1). Next we washed and eluted affinitycaptured material, digested it with trypsin and analyzed it by liquid chromatography-electrospray ionization time-of-flight mass spectrometry (LC-ESI TOF MS). We quantified sample-derived ubiquitin species using the ratio of ion intensities of the tracked endogenous peptides to labeled synthetic peptides (added during trypsinization to quantify material in the digest) and the protein standard-derived peptides (added to lysates to determine recovery) (Online Methods, Fig. 1c and Supplementary Data 1) . To calculate the concentration of monoubiquitinated substrates, we subtracted amounts of measured free ubiquitin and polyubiquitin chains from measured total ubiquitin.
The addition of isotope-labeled protein standards to lysates and peptide standards to trypsin digestions enabled the determination of the recovery efficiency of ubiquitin conjugates throughout the isolation procedure, including capture by the affinity reagents. The extent of recovery depends on many parameters and is hindered by dilution and residual SDS, which is necessary to reduce deubiquitinating-enzyme activity. Typical recovery by the BUZ affinity reagent was typically 1-3%. Sample recovery using the hP2 UBA domain was typically 10-40%. Under the conditions used, we detected no binding of substrate-linked ubiquitin chains from our polyubiquitin standard binding to the BUZ domain, and the recovery of free ubiquitin with the hP2 UBA was ~0.03%, indicating that the bulk of polyubiquitin binding to hP2 UBA was due to avidity effects. To ensure accurate quantification of ubiquitin pools, we quantified the efficiency of recovery for each individual pulldown and carried this through into all calculations.
Assay performance and reproducibility
We assessed the feasibility of measuring total ubiquitin by BUZenriched Ub-PSAQ relative to free [ 13 C]ubiquitin standard and compared the results to those obtained with an established indirect competitive ELISA 14 (Fig. 2a) . The sensitivity of Ub-PSAQ was comparable to that of the ELISA, with accurate and precise ubiquitin measurement down to ~10 ng (1.2 pmol). The PSAQ signal was linear over a range of three orders of magnitude of useful working concentrations. The percentage error associated with quantifying ubiquitin by AQUA mass spectrometry using ions from two equivalent linear tryptic peptides, TLSDYNIQK (amino acids 55-63; TLS) and ESTLHLVLR (amino acids 64-72; ESTL), was typically less than 20% (Supplementary Fig. 2 ). To ensure accurate quantification of ubiquitin, we averaged data derived from these two ions as previously described for synthetic peptide AQUA 10 . We first assessed the Ub-PSAQ method by measuring defined mixtures of unlabeled versions of our ubiquitin protein standards with varying ratios of free ubiquitin and conjugate species relative to isotope-labeled protein standards (Fig. 2b-e) . These data indicate that Ub-PSAQ can accurately report the amounts of each ubiquitin species over an approximately fivefold range of relative abundance in the mixtures and that the relative abundance of each individual species does not impact the accurate measurement of the other species.
ubiquitin pool distribution in cells and tissue
To determine total ubiquitin concentration in HEK293 cells by Ub-PSAQ, we treated HEK293 cell lysate with the deubiquitinating enzyme usp2cc, which releases free ubiquitin from all ubiquitin conjugates, and measured sample-derived ubiquitin relative to the 13 C-labeled free ubiquitin standard after enrichment with the BUZ affinity reagent. In close agreement with previously reported values for the same cell line measured by ELISA 14 , we determined HEK293 ubiquitin total concentration to be 486.4 ± 42 pmol mg −1 total protein (±s.d.; n = 9), corresponding to a molar concentration of ~85 µM, ~8 × 10 7 molecules per cell or ~0.42% (weight ubiquitin/weight total protein).
We assessed the ubiquitin pool distribution in two cell lines, and in mouse and human brain tissues by Ub-PSAQ. Although HEK293 cells have about twofold more total ubiquitin than a mouse embryonic fibroblast (MEF) cell line, these cell lines have similar ubiquitin pool distributions with ~65% of ubiquitin present as monoubiquitinated substrates, ~23% as free ubiquitin and ~11% as polyubiquitin chains ( Table 1) . This distribution is consistent with the results of a prior study in which ubiquitin conjugates had been measured as a singular entity and found to reflect ~30-80% of cellular ubiquitin in various cell lines 7 . By contrast, our quantification of ubiquitin pools in mouse brain revealed that 59% of ubiquitin is present as free monomer, 35% as monoubiquitin on substrates and 5% as polyubiquitin chains ( Table 1) . In human frontal cortex, 82% of ubiquitin is free ubiquitin monomer, 13% is present as monoubiquitin on substrates and 4% is present as polyubiquitin chains ( Table 1) . We analyzed the major (Lys48, Lys63 and Lys11) ubiquitin-ubiquitin chain linkages in cell and tissue samples ( Table 1) . Although we could detect other polyubiquitin linkages (Lys6, Lys27, Lys29 and Lys33) in these samples, together they constitute less than 1% of total ubiquitin (data not shown) and were not included in this analysis. In sum, the steady-state distribution of ubiquitin among the different pools differs markedly between cell lines and brain tissue. The precision and reproducibility of measured ubiquitin pool component concentrations were excellent in mouse brain lysate, with intra-assay (10 technical replicates measuring the same lysate within one assay with a single standard mixture) and interassay (4 technical replicates measuring the same lysate on different days with individually prepared standard mixtures) coefficients of variation less than 10% for total and free ubiquitin and less than 20% for ubiquitin chains and monoubiquitinated substrates ( Table 1 and Supplementary Fig. 3 ).
effect of acute proteasome inhibition on ubiquitin pools
To determine the distribution of ubiquitin pools before and after induction of proteasome stress, we measured ubiquitin pools in HEK293 and MEF cells after acute exposure to the proteasome inhibitor MG-132 ( Fig. 3 and Supplementary Fig. 4 ). As expected, the major effect of MG-132 was to increase the abundance of ubiquitin chains, clearly evident from Ub-PSAQ and immunoblot analysis ( Fig. 3 and Supplementary Fig. 4) . In MEF cells, the sixfold increase in the abundance of polyubiquitin chains (Fig. 3b) at 12 h was accompanied by a twofold increase in free ubiquitin and monoubiquitinated substrates, leading to a robust increase in total ubiquitin, consistent with the previously reported transcriptional activation of ubiquitin gene expression by acute proteasome inhibition in MEFs 15 . In contrast, the increase in the abundance of polyubiquitin chains in HEK293 cells was not accompanied by an increase in total ubiquitin or other ubiquitin species, suggesting that the ubiquitin incorporated into chains in HEK293 cells treated with the proteasome inhibitor MG-132 may be derived principally from other cellular ubiquitin pools as opposed to de novo synthesis of additional ubiquitin. Indeed amounts of free ubiquitin and monoubiquitin on substrates were reduced (although not significantly P ≤ 0.05) in parallel with the increase in polyubiquitin chains (Fig. 3a) . In agreement with prior work 16, 17 , we observed a decrease in monoubiquitin conjugates linked to histones in MG-132-treated HEK293 cells (Fig. 3d,e and Supplementary Figs. 5 and 6), likely reflecting a redistribution of ubiquitin pools during proteasomal stress.
Although Lys48-linked polyubiquitin chains are widely held to be the canonical signal for proteasome-mediated degradation, other polyubiquitin linkages have also been implicated in proteasomal targeting 18, 19 . After 12 h of proteasome inhibition in the MEF cell line, we observed an approximately tenfold increase in Lys48-linked chains and a three-to fourfold increase in Lys63-and Lys11-linked chains (Supplementary Fig. 4 ). However, in HEK293 cells we observed a trend toward an approximately twofold increase in all polyubiquitin linkages by 12 h of treatment with MG-132, consistent with previous reports 8, 18, 19 ( Supplementary  Fig. 4) . The accumulation of Lys63-and Lys11-linked ubiquitin chains in addition to Lys48-linked chains could suggest that cells use multiple types of polyubiquitin chains as proteasome-targeting signals or reflect the existence of mixed-linkage polyubiquitin chains or of multiple chain types on individual proteins 20, 21 . The differences in the kinetics of increase of the different polyubiquitin chain linkages, with a trend toward Lys48-and Lys11-linked polyubiquitin chains increasing at the 2 h time point, may suggest that Lys63-linked chains are unlikely to be a major proteasome-targeting signal. Overall, these data suggest that ubiquitin pool dynamics in response to proteasome stress differ greatly between these two cell types.
ubiquitin pools in cytosolic and histone-enriched fractions
To understand the surprisingly high proportion of total ubiquitin present as monoubiquitin conjugates in cell lines (~65%), we used Ub-PSAQ to determine the fraction of monoubiquitin conjugates present in a cytosolic fraction and in a histone-enriched fraction prepared by acid extraction of a nuclear fraction from HEK293 cells (Supplementary Fig. 5 ). As expected, the histone fraction was highly enriched in monoubiquitin conjugates, with 91% of all ubiquitin in this fraction present as monoubiquitin-conjugated substrates (Fig. 4a) , and accounting for ~23% of total cellular ubiquitin and ~34% of total cellular monoubiquitin conjugates (Fig. 4b) . The remaining ~10% of ubiquitin associated with the histone fraction was approximately equally distributed between free ubiquitin and chain conjugates (Fig. 4c) . The latter pool was somewhat enriched in Lys63 linkages, perhaps reflecting a high proportion of histone-associated DNA-repair enzymes, though we cannot speculate as to which substrates are modified by Lys63-linked ubiquitin chains.
discussion
The Ub-PSAQ method overcomes several problems commonly encountered in quantifying ubiquitin. First, the use of two affinity reagents that interact with ubiquitin through distinct surfaces allows the purification of specific ubiquitin pool components. Second, the use of usp2cc enables the conversion of all ubiquitin species to free ubiquitin and the accurate measurement of total ubiquitin 12, 14 . Third, lysis of cells or tissues in the presence of 5 mg ml −1 NEM and 2% SDS prevents interconversion of ubiquitin species during lysis and sample processing. Finally, the method enables the analysis of sample-and protein standardderived ubiquitin species directly after affinity capture without the need for SDS-PAGE steps that can confound quantification of complex analytes.
One potential limitation of the Ub-PSAQ method as implemented here is that it assumes that all ubiquitin-ubiquitin linkages bind with equal affinity to the hP2 UBA affinity reagent. Although data demonstrate that the UBA domains of ubiquilin-Plic family members bind ubiquitin Lys48 and ubiquitin Lys63 chains without linkage specificity 22, 23 , not all linkages have been examined. Furthermore, it is possible that polyubiquitin chains measured binding to the hP2 UBA domain are underestimated owing to effects of chain length on binding affinity 22, 24 and to the effect of ubiquitin molecules at the end of chains, which do not contribute an isopeptide bond and are therefore not included in chain calculations. Prior work has demonstrated that the BUZ domain of IsoT binds ubiquitin via free C termini and that this reagent is unlikely to exhibit bias owing to ubiquitin-chain linkage type or length 13 .
The average length of cellular ubiquitin chains has, to our knowledge, not been reported. It will be important to generate a wider variety of isotope labeled ubiquitin protein standards and to extend the Ub-PSAQ method to obtain a more detailed picture of the abundance of ubiquitin species, including determining average chain lengths in cells.
Another potential limitation is that it may not be possible to measure all ubiquitin species simultaneously. For instance, although we observed binding of free, unanchored ubiquitin chains to the BUZ affinity reagent (Supplementary Data 1) , their basal levels were low. Compounded with the low recovery by the BUZ domain under the conditions we used, the values for these species are too close to the noise to discern in the present work. Simple remedies, such as using larger samples for the BUZ domain capture should enable precise assessment of the concentration of free ubiquitin chains. Similarly, it should be possible to adapt the methods reported here to measure the abundance of thioesterlinked ubiquitin in biological samples. We cannot currently estimate the abundance of thioester linked ubiquitin because the half-life of thioester-linked ubiquitin species at near-physiological pH is short relative to the time required for sample processing and affinity capture 25 . Consistent with this expectation, we observed no dithiothreitol-releasable ubiquitin binding to the BUZ domain in preliminary experiments (data not shown). The general Ub-PSAQ method is versatile and could be readily extended by introducing new affinity reagents, such as chainspecific antibodies 26 , other ubiquitin binding domains or new standards (multiple types of ubiquitin chain standards with different linkages present as different isotope-labeled ubiquitin species, thioester linked ubiquitin species and free ubiquitin chains) to enable increasingly comprehensive quantification of specific species using the overall approach described.
Ubiquitin is important in many facets of biology because of its ability to reversibly form a diverse array of conjugates with other proteins and the ability of these conjugates to act as signals in a diverse set of biological processes 1,2 . Our work enables, to our knowledge for the first time, accurate and precise measurement of ubiquitin distribution among different cellular pools and will therefore be a valuable tool to facilitate our understanding of this important signaling molecule. Ubiquitin preparation. Full-length, wild-type human ubiquitin was expressed from the pet3a expression vector (Novagen) in Escherichia coli. BL21 (DE3) pLysS RIL cells were transformed with expression vector and grown in a 2 l Fernbach flask to OD 600 1.0 in LB medium with 0.1 mg ml −1 ampicillin at 37 °C. Heterologous protein expression was then initiated with 1 mM IPTG for 4 h. Cells were collected by centrifugation and frozen in liquid nitrogen.
For ubiquitin purification, frozen bacterial cells were resuspended in a lysis buffer consisting of 50 mM Tris (pH 7.5), 150 mM NaCl, 10% (v/v) glycerol, 1% (v/v) Triton X-100, 1 mM EDTA and Complete protease inhibitor tablets (Roche). Resuspended cells were lysed using sonication followed by two passes through a French press at 10,000 pounds per square inch (p.s.i.). Lysate was clarified by centrifugation at 40,905g (18,500 r.p.m. in a Sorvall SS-34 rotor) for 60 min. Glacial acetic acid was added dropwise with mixing until the solution reached pH 4. Precipitate was then cleared by centrifugation at 20,199g (13,000 r.p.m. for 20 min in a Sorvall SS-34 rotor). After centrifugation, the ubiquitin-containing supernatant was dialyzed twice into 25 mM sodium acetate (pH 4.5), loaded onto a HiTrapSP XL 5 ml (GE) column and eluted with a linear gradient of sodium chloride from 0 mM to 500 mM NaCl. Ubiquitin was then purified by gel filtration chromatography on a Sephacryl S-200 (GE) column equilibrated with 50 mM Tris (pH 7.5), 500 mM NaCl and 1 mM DTT, and then dialyzed into 25 mM HEPES (pH 7.5) and frozen in liquid nitrogen.
Glutathione-S-transferase (GST)-Rsp5(196-809) preparation.
Sequence encoding residues 196-809 of Rsp5 (lacking the N-terminal C2 domain) was subcloned into pGEX-4T and confirmed by sequencing. BL21 (DE3) cells were transformed with expression vector and grown to OD 600 1.0 in LB medium with 0.1 mg ml −1 ampicillin at 37 °C. The temperature was then shifted to 30 °C, and expression was initiated with 1 mM IPTG for 6 h. Cells were collected by centrifugation and frozen in liquid nitrogen. For purification, cells were resuspended in a lysis buffer consisting of 50 mM Tris (pH 8.0), 250 mM NaCl, 5 mM EDTA, 10 mM DTT, 1% Triton X-100 and Complete protease inhibitor tablets, and lysed by sonication followed by two passes through a French press at 10,000 p.s.i. Lysate was cleared by centrifugation before incubation with glutathione sepharose resin for 2 h. The resin was washed 3 times with 10 bed volumes of lysis buffer and protein was eluted with lysis buffer supplemented with 20 mM glutathione (pH adjusted to 7.5). After dialysis into 50 mM Tris (pH 7.5), 50 mM NaCl, 5 mM DTT, GST-Rsp5(196-809) was loaded onto a HiTrapQ XL 5 ml column, eluted with a linear gradient from 50 to 500 mM NaCl, and dialyzed into 20 mM Tris (pH 7.5) and 2 mM DTT, and frozen in liquid nitrogen.
E2-Ubc4 preparation. BL21 (DE3) cells were transformed with pet15b-Ubc4 (gift of D. Rotin, University of Toronto) and grown to OD 600 1.0 in LB medium with 0.1 mg ml −1 ampicillin at 37 °C. Heterologous protein expression was then initiated with 0.4 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 4 h. Cells were collected by centrifugation and frozen in liquid nitrogen. For purification, cells were resuspended in a lysis buffer consisting of 50 mM Tris (pH 7.6), 300 mM NaCl, 20 mM imidazole, 10% glycerol, 0.2% Triton X-100, 1 mM PMSF and EDTA-free Complete protease inhibitor tablets, and lysed by sonication followed by two passes through a French press at 10,000 p.s.i. Lysate was cleared by centrifugation before incubation with nickel-nitrilotriacetic acid resin for 2 h. The resin was washed 5 times with 10 bed volumes of lysis buffer and protein was eluted with lysis buffer supplemented with 250 mM imidazole (pH 8). The eluate was dialyzed into 50 mM Tris (pH 7.6), 150 mM NaCl, 10% glycerol and 1 mM DTT before filtration through a 50,000 molecular weight cutoff (MWCO) ultrafiltration membrane and concentration on a 5,000 MWCO ultrafiltration membrane. Protein concentration was determined by bicinchoninic acid (BCA) protein assay (Pierce) relative to a BSA standard, and was diluted to 45 µM with dialysis buffer and frozen in liquid nitrogen.
Ubiquitin-GFP preparation. Sequence encoding GFP was cloned in-frame with sequence encoding N-terminal 6His-tagged ubiquitin (gift of C. Patel, Stanford University) in the pHUE vector (gift of R. Baker, Australian National University). BL21 (DE3) cells were transformed with expression vector and grown to OD 600 1.0 in LB medium with 0.1 mg ml −1 ampicillin at 37 °C. The temperature was then shifted to 30 °C, and expression was initiated with 1 mM IPTG for 6 h. Cells were collected by centrifugation and frozen in liquid nitrogen. For purification, cells were resuspended in a lysis buffer consisting of 50 mM Tris (pH 7.5), 650 mM NaCl, 10% glycerol, 1% Triton X-100, 20 mM imidazole and EDTA-free Complete protease inhibitor tablets, and lysed by sonication followed by two passes through a French press at 10,000 p.s.i. Lysate was cleared by centrifugation before incubation with nickel-nitrilotriacetic acid resin for 4 h. The resin was washed 3 times with 10 bed volumes of lysis buffer and protein was eluted with lysis buffer supplemented with 200 mM imidazole (pH 8). After dialysis into 50 mM Tris (pH 7.5), 50 mM NaCl, 5 mM DTT, ubiquitin-GFP was loaded onto a HiTrapQ XL 5 ml column, eluted with a linear gradient from 50 to 500 mM NaCl, dialyzed into 50 mM Tris (pH 7.5), 150 mM NaCl, 10% glycerol, 5 mM DTT and frozen in liquid nitrogen.
hPlic2 UBA domain preparation. BL21 (DE3) cells were transformed with pet21-hPlic2(575-624) expression vector (gift of E. Bennett, Stanford University) and grown to OD 600 1.0 in LB medium with 0.1 mg ml −1 ampicillin at 37 °C. The temperature was then shifted to 30 °C, and expression was initiated with 1 mM IPTG for 6 h. Cells were collected by centrifugation and frozen in liquid nitrogen. For purification, cells were resuspended in a lysis buffer consisting of 50 mM Tris (pH 7.5), 650 mM NaCl, 10% glycerol, 1% Triton X-100, 20 mM imidazole and EDTAfree Complete protease inhibitor tablets, and lysed by sonication followed by two passes through a French press at 10,000 p.s.i. Lysate was cleared by centrifugation before incubation with nickel-nitrilotriacetic acid resin for 4 h. The resin was washed 3 times with 10 bed volumes of lysis buffer, 3 times with 10 bed volumes of 50 mM Tris (pH 8) and eluted with 50 mM Tris (pH 8) supplemented with 200 mM imidazole (pH 8). The eluted protein was dialyzed into 50 mM HEPES pH 7.0, 100 mM NaCl, 2 mM DTT before conjugation to Affigel10 (Biorad) beads at 1 mg ml −1 per the manufacturer's instructions.
IsoT BUZ domain preparation. A C-terminal 6His tag was added to pRS-ISOT(163-291) (gift of K. Wilkinson, Emory University) and confirmed by sequencing. BL21 (DE3) cells were transformed with expression vector and grown to OD 600 1.0 in LB medium with 0.1 mg ml −1 ampicillin and 50 µM ZnSO 4 at 37 °C. The temperature was then shifted to 30 °C and expression was initiated with 1 mM IPTG for 6 h. Cells were collected by centrifugation and frozen in liquid nitrogen. For purification of IsoT(163-291)-6His, cells were resuspended in a lysis buffer consisting of 50 mM Tris (pH 7.5), 650 mM NaCl, 10% glycerol, 1% Triton X-100, 20 mM imidazole and EDTA-free Complete protease inhibitor tablets, and lysed by sonication followed by two passes through a French press at 10,000 p.s.i. Lysate was cleared by centrifugation before incubation with nickel-nitrilotriacetic acid resin for 4 h. The resin was washed 3 times with 10 bed volumes of lysis buffer and protein was eluted with lysis buffer supplemented with 200 mM imidazole (pH 8). After dialysis into 50 mM Tris (pH 7.5), 50 mM NaCl, 5 mM DTT, BUZ domain was loaded onto a HiTrapQ XL 5 ml column, eluted with a linear gradient from 50 to 500 mM NaCl, concentrated and purified by gel filtration chromatography on a Sephacryl S-200 column equilibrated with 50 mM Tris (pH 7.5), 500 mM NaCl and 1 mM DTT, then dialyzed into 50 mM HEPES (pH 7.2), 100 mM NaCl and 2 mM DTT, and frozen in liquid nitrogen. BUZ domain was conjugated to Affigel10 beads at 1 mg ml −1 per the manufacturer's instructions.
Stable-isotope labeling. All stable isotope-labeled proteins were prepared by growing BL21 cells in M9 minimal medium prepared with either 15 N-containing ammonium chloride (0.5 g l −1 ) or [ 13 C]glucose (2.5 g l −1 ) or both, as appropriate. Cells were grown through two M9 medium starter cultures containing appropriate isotopes before inoculating the growths to minimize contamination with inappropriate isotopes. Expression was induced by addition of 1 mM IPTG after the temperature was shifted to 30 °C at OD 600 0.7. After 18 h of induction, cells were collected by centrifugation, frozen in liquid nitrogen and proteins were purified as described above.
The intact molecular weight of each protein purified was confirmed by mass spectrometry, and >98% isotope labeling was additionally confirmed by inspection of tryptic peptide masses.
Peptides and antibodies. Synthetic peptides were from Cell Signaling Technologies or Biopeptide LLC and were confirmed by tandem mass spectrometry (MS/MS) and quantified by amino acid analysis. Ubiquitin antibodies used for western blotting were FK2 (Biomol) and A100 (Boston Biochem).
Production of polyubiquitinated protein standard. autoubiquitination was performed at 17 µM E3 with 0.125 µM E1 (Boston Biochem E-304), 1.125 µM E2, 250 µM ubiquitin (unlabeled or isotope-labeled as appropriate), in 50 mM HEPES (pH 7.5), 2 mM ATP, 5 mM MgCl 2 , 2 mM DTT and 0.05% Triton X-100. The reaction was allowed to proceed overnight at room temperature (18-21 °C) and ubiquitin was quantitatively consumed by the reaction. Polyubiquitinated was then purified by binding to glutathione sepharose, washed with a buffer containing 50 mM Tris (pH 7.5), 150 mM NaCl, 2 mM DTT and 1% Triton X-100, and then eluted with 50 mM HEPES (pH 7.4), 500 NaCl, 1% Triton X-100, 10% glycerol, 2 mM DTT, 20 mM glutathione and 0.05% SDS. The polyubiquitinated protein standard contained an average of 1.3 ubiquitin chains per Rsp5 molecule, with an average chain length of 12.5 ubiquitin proteins (Supplementary Fig. 1b and Supplementary  Table 1 ). Standard-derived and sample-derived ubiquitin ions were well resolved from one another in the mass spectrometer (Supplementary Fig. 1d ).
Protein standard absolute quantification (PSAQ) method. All protein standards used for mass spectrometry were quantified by two or more of the following methods: amino acid analysis, direct AQUA mass spectrometry and absorbance at 280 nm. Quantifications by the different methods were in excellent agreement for all standards.
Frozen cells or tissues were lysed in 20 mM HEPES (pH 7.2), 150 mM NaCl, 10% glycerol, 1% Triton X-100, 5 mg ml −1 NEM, 2% SDS and EDTA-free Complete protease inhibitors (Roche). Cells were lysed by sonication, whole mouse brain was lysed in a PotterElvehjem homogenizer, then by sonication, and human frontal cortex tissue samples were lysed by using FastPrep Lysing Matrix D (MP Biomedicals) per manufacturer's instructions. Extracts were centrifuged at 20,800g (14,000 r.p.m. in a microcentrifuge) for 10 min, and supernatants quantified by using the bicinchoninic acid (BCA) assay. Defined molar amounts of isotope-labeled free ubiquitin ( 13 C) (typically ~40 pmol), substrate-linked ubiquitin ( 15 N) chain protein (typically ~10 pmol) and double-labeled ( 13 C and 15 N) ubiquitin-GFP (typically ~40 pmol) standards were added to samples (typically 1 mg of cell lysate) and incubated for 1 h at room temperature before DTT was added to 60 mM to quench NEM. Samples were then divided into two fractions and diluted into the same buffer lacking NEM, SDS and protease inhibitors, and containing 2 mM DTT to reduce the concentration of SDS to 0.05% or below. Typically ~150 µl lysate at ~3 mg ml −1 was diluted to 15 ml. After dilution (Fig. 1) , one sample was treated with the deubiquitinating enzyme usp2cc to convert all ubiquitin species to free ubiquitin to enable the measurement of total ubiquitin levels, and the other was not treated with deubiquitinating enzyme to allow measurement of free ubiquitin species and ubiquitin chains. After overnight pulldowns with 50 µl BUZ and hP2UBA beads, affinity captured material was washed twice with 0.5 ml dilution buffer then twice with 50 mM ammonium bicarbonate (pH 8.0) before elution with 0.1% Rapigest (Waters) in 50 mM ammonium bicarbonate (pH 8.0). Then 10 pmol of synthetic AQUA peptide standards were added and then 1 µg trypsin was added. To confirm that our lysis conditions prevented deubiquitinating enzyme activity, we monitored binding of the [ 15 N, 13 C]ubiquitin-GFP standard by the BUZ affinity reagent in all samples, and observed none when samples were lysed in the presence of 2% SDS and 5 mg ml −1 NEM, consistent with polyubiquitin chain stability observed over 48 h by western blotting (Supplementary Fig. 7) .
After trypsinization overnight at 37 °C and hydrolysis of Rapigest per manufacturer's instructions with HCl, samples were separated on a C-18 reversed-phase column and directly analyzed by inline ESI-TOF MS as described previously 8 . Absolute quantification was performed using the ion intensities of the tracked endogenous peptides relative to the spiked labeled synthetic and protein-derived peptides. Peptide identities were confirmed by LC-MS/MS analysis as described previously 8 .
For The concentration of free ubiquitin species isolated with the BUZ resin were calculated using the ratio of sample-derived ubiquitin species relative to the 13 C-labeled free ubiquitin standard and appropriate AQUA standards (Supplementary Data 1) . Total ubiquitin was measured after the conversion of all ubiquitin species to free ubiquitin with usp2cc and enrichment with BUZcoupled resin relative to the 13 C-labeled free ubiquitin standard. Polyubiquitin chains were isolated by affinity capture with hP2 UBA-coupled resin. Ubiquitin chain recovery was measured as recovery of the [ 15 N]UbK63 chain standard (comparing the abundance of the [ 15 N]UbK63 tryptic isopeptide to the UbK63 AQUA isopeptide standard reveals what fraction of the known molar amount of standard added was observed in the tryptic digest). Other ubiquitin-ubiquitin linkages were quantified in the tryptic digest relative to the appropriate AQUA standard and then normalized using the recovery determined with the UbK63 chain standard (Supplementary Data 1) .
As no known reagents can specifically enrich monoubiquitinated substrates but not free ubiquitin or ubiquitin chains, we computed the amount of monoubiquitinated substrates: monoubiquitin = total ubiquitin − free ubiquitin − chain ubiquitin.
We conservatively estimate that we added on the order of 2,000 pmol of active ubiquitin binding sites to typical hP2 UBA or BUZ pulldowns (this assumes that ~50% of protein coupled is not competent for binding ubiquitin). The maximum amount of ubiquitin input to any individual pulldown in this study was ~650 pmol (Fig. 2b; ~1 ,300 pmol total ubiquitin split between two pulldowns) and more typical pulldowns contained 50% to 25% as much input ubiquitin. With the recovery efficiencies discussed above and the relatively low fraction of ubiquitin chain even in MG-132 treated lysates, we were in a regime with substantial excess binding sites. However, we expect that the method would work equally well in a regime in which beads are completely saturated because the recovery standards would still be expected to enable the determination of the ratio of sample-derived to standardderived species.
Conversion of HEK293 cell ubiquitin concentration to molarity. The protein content of HEK293 cells was measured using a BCA assay relative to a BSA standard (263 ± 19 pg per cell). Using an estimated HEK293 cell volume of 1.5 pl we calculate that the observed HEK293 cell ubiquitin concentration of 486.4 pmol mg −1 corresponds to a molar concentration of ~85 µM.
Cells and fractionation.
Mouse samples were obtained from our lab's mouse colony under our institutional review board approval; human brain samples were obtained from D. Dickson (Mayo Clinic, Jacksonville Florida, USA) under a grant subcontract and covered by D. Dickson's institutional review board approval. Cell culture was performed as previously described 27 . Briefly, HEK293 or m5-7 MEF cells (gift of N. Mizushima and N. Hosokawa, Tokyo Metropolitan Institute of Medical Science) 28 were maintained in Dulbecco's Modification of Eagle's Medium (DMEM) with 4.5 g l −1 glucose and l-glutamine without sodium pyruvate (Mediatech) containing 10% FBS at 37 °C in 5% CO 2 . For time-course experiments with proteasome inhibitor MG-132 (Enzo Life Sciences), the final concentration was 1 µM for the times indicated. For MG-132 treatment in histone experiments, HEK293 cells were treated with DMSO (vehicle) or MG-132 (10 µM) for 6 h. Nuclear-cytosolic fractionation was performed as described previously 29 . Acid extraction of histones was performed as described previously 30 . Briefly cells were lysed in hypotonic lysis buffer (10 mM Tris-Cl (pH 8.0), 1 mM KCl, 1.5 mM MgCl 2 , 1 mM DTT, 1 mM PMSF, 40 mM NEM and Complete protease inhibitor cocktail) and incubated for 30 min on rotator at 4 °C. Nuclei were pelleted by centrifugation at 10,000g for 10 min at 4 °C. Pelleted nuclei were extracted with 0.4 N H 2 SO 4 , incubated on a rotator for 30 min at 4 °C followed by centrifugation at 16,000g for 10 min at 4 °C. The resulting supernatant (histone-enriched fraction) was dialyzed into water overnight and the following day the solvent removed by Speedvac. The histone-enriched fraction was then dissolved in water for processing by PSAQ.
Statistical analysis. Single, double and triple asterisks denote P ≤ 0.05, P ≤ 0.01, P ≤ 0.005, respectively. The significance levels were determined using the unpaired t-test. 
